Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- Drug: cis-platinumRadiation: radiationDrug: Envafolimab InjectionDrug: Recombinant Human Endostatin Injection
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05879796
Study on Dynamic Environmental Exposome of ICU and the Establishment of Microbial Transmission Model Between Environment and Host
Active, not recruiting
- Conditions
- Ventilator-associated PneumoniaHospital Acquired Infection
- Interventions
- Procedure: Expectoration care
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05877625
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Clinical Application of a Self Stabilizing Atlantoaxial Fusion Cage
Not yet recruiting
- Conditions
- Atlantoaxial Dislocation
- Interventions
- Device: New type of self stabilizing atlantoaxial fusion cage
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT05876611
the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening
Recruiting
- Conditions
- Colorectal Adenoma
- Interventions
- Diagnostic Test: PrecogColo Dx test
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT05870696
- Locations
- 🇨🇳
Beijing Huaxin Hospital, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Aerospace Center Hospital, Beijing, Beijing, China
Analysis of Radiographic and Kinematic Features in FAI Patients
Completed
- Conditions
- Femoro Acetabular Impingement
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT05867069
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Surgical Treatment of Irreducible Atlantoaxial Dislocation
Not Applicable
Recruiting
- Conditions
- Irreducible Atlantoaxial Dislocation
- Interventions
- Procedure: Anterior and posterior treatment strategyProcedure: Simple posterior approach treatment strategy
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05847270
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Correlation Between Preoperative Knee Extension Lag and Functional Outcome After Total Knee Arthroplasty
Not yet recruiting
- Conditions
- Extension LagTotal Knee Arthroplasty
- Interventions
- Procedure: total knee arthroplasty
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05833152
Ultrasound Imaging of Fibrotic Tissue
Recruiting
- Conditions
- Arthrofibrosis of KneeArthrofibrosis of Shoulder
- Interventions
- Other: Physical Therapy
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05818904
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Displacement Distance and Stabilization Time for Liver Fiducial Marker
Recruiting
- Conditions
- Liver Cancer
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05816837
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, United Kingdom Of Great Britain And Northern Ireland, China
🇨🇳Department of Radiation Oncology of Peking university third hospital, Beijing, China
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
Early Phase 1
Recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: ZVS203e
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT05805007
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath